Eng C, Kindler H L, Schilsky R L
Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 2115, USA.
Clin Colorectal Cancer. 2001 Aug;1(2):95-103. doi: 10.3816/CCC.2001.n.009.
5-Fluorouracil (5-FU) has been utilized as part of standard chemotherapy for treatment of early-stage and metastatic colorectal cancer for more than 4 decades. The oral fluoropyrimidines have been studied extensively as an alternative to intravenous 5-FU. The goal of such an approach is to simplify drug administration and to improve the toxicity profile while maintaining efficacy that is at least equivalent to intravenous therapy. The goal of this article is to review the features of the main oral 5-FU prodrugs, which include capecitabine, uracil and tegafur (UFT)/leucovorin, S-1, and BOF-A2 and to describe their potential efficacy in treating colorectal cancer.
5-氟尿嘧啶（5-FU）作为标准化疗的一部分用于治疗早期和转移性结直肠癌已有40多年。口服氟嘧啶类药物作为静脉注射5-FU的替代药物已得到广泛研究。这种方法的目的是简化给药方式并改善毒性特征，同时保持至少等同于静脉治疗的疗效。本文的目的是综述主要口服5-FU前体药物的特点，包括卡培他滨、尿嘧啶和替加氟（UFT）/亚叶酸、S-1和BOF-A2，并描述它们在治疗结直肠癌方面的潜在疗效。
